CEACAM5 and colorectal carcinoma: Radioconjugates targeting CEA have been used in early phase clinical trials in CRC (Wong et al, 2004; Liersch et al, 2005), but there is so far no unconjugated anti-CEA antibody licensed for treatment (Blumenthal et al, 2008).